While the role of PPARγ in tumor sites remains poorly defined, the thiazolidinedione family of PPARγ agonists, such as troglitazone (TGZ), pioglitazone (PGZ) and rosiglitazone, have been shown to regulate growth and survival in a number of cancer cell lines [10], suggesting that TGZ may serve as an effective approach for the treatment of pancreatic cancer. The gene discussed is PPARG; the disease is familial pancreatic carcinoma.